Juventas CAR-T LBCL Launch Marks Second Indication
Juventas Cell Therapy Ltd announced the commercial launch of inaticabtagene autoleucel for relapsed or refractory...
BMS Breyanzi MZL FDA Approval First CAR-T
Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the FDA has approved Breyanzi (lisocabtagene maraleucel; liso-cel)...
Formosa Pharma APP13007 Clobetasol ASEAN Deal with Rxilient
Formosa Pharmaceuticals, Inc. (TPE: 6838) announced an exclusive licensing agreement with Rxilient Medical Pte. Ltd.,...
Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint
Novo Nordisk (NYSE: NVO) reported at the Clinical Trials on Alzheimer’s Disease conference that semaglutide...
Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures
Acotec Scientific Holdings Limited (HKG: 6669) announced it has received registration approval from China’s National...
Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes
Youjia Biomedical Technology and Hangzhou Tongee Medical Technology Co., Ltd officially signed a strategic cooperation...
Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its FXS0887 tablet has...
TransThera Tinengotinib Cholangiocarcinoma Priority Review China
TransThera Sciences (Nanjing) Inc. (HKG: 2617) announces that Tinengotinib tablets have been included in the...
Bio-Sincerity UCAS R&D Center Pharma Synthesis
Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (SHE: 301096) announced the signing of a cooperation agreement with...
Sino-Biopharm TQF3250 GLP-1 Capsule Wins FDA Clinical Approval for Weight Loss
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited...
Gene-Mink CAR-NK BCMA Therapy Wins China Approval for Multiple Myeloma
Beijing Gene Mink Biotechnology announced that its self-developed QM103 Cell Injection, a BCMA‑targeted CAR‑NK cell...
CSPC SYH2056 FDA Approval Targets Depression with 5-HT2A Agonist
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that SYH2056 tablets, a Category 1 chemical drug, has...
Antengene XPOVIO sNDA Hong-Kong Approval Expands MM DLBCL Indications
Antengene Corporation Limited (HKG: 6996) announced that Hong Kong’s Department of Health approved two supplementary...
Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership
Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Investigational New Drug (IND) application for DB-1324,...
NHSA Guangzhou Drug-List Conference Releases 2025 Medical Insurance Formulary
The National Healthcare Security Administration (NHSA) announced it will host the 2025 Innovative Drugs High-Quality...
Simcere deuremidevir RSV Licensing Deal Targets China Breakthrough
Simcere Pharmaceutical Group Limited (HKG: 2096) and Vigonvita Life Sciences Co., Ltd. (HKG: 2630) entered...
Henlius Fovinaciclib CDK4-6 Breast-Cancer China Commercialization
Henlius Biotech (HKG: 2696) announced a collaboration with Avanc Pharmaceutical Co., Ltd. to advance the...
Hengrui Remimazolam ICU Sedation NMPA Application Accepted
Jiangsu Hengrui Pharmaceutical Co., Ltd (SHA: 600276, HKG: 1276) announced that China’s National Medical Products...
Novo Nordisk CagriSema Pediatric Obesity Trial to Enroll 460 Children
Novo Nordisk (NYSE: NVO) is planning to test its experimental obesity drug CagriSema in overweight...
Antengene ATG-022 CLDN18.2 ADC Gets China Nod for Keytruda Combo in Gastric Cancer
Antengene Corporation Limited (HKG: 6996) announced that China’s National Medical Products Administration (NMPA) has approved...